Compare Incyte Corporation (INCY) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs SiTime Corporation — how do they compare? Incyte Corporation trades at $118.05 (market cap $23.11B), while SiTime Corporation trades at $582 (market cap $16.63B). The key difference: Incyte Corporation is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals.
| INCY | SITM | |
|---|---|---|
Market Cap | $23.11B | $16.63B |
Sector | Health | Technology |
52-Week High | $118.52 | $901.60 |
52-Week Low | $67.38 | $190.16 |
Enterprise Value | $19.13B | $15.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
SITM trades at $555.15, showing minimal daily movement with a bearish technical signal despite recent earnings beats. The company reported strong revenue growth and completed the acquisition of Renesas' timing business, but faces negative net income margins and high valuation multiples. Analyst consensus remains strongly bullish with a $825 price target, highlighting growth potential from AI infrastructure demand.
The outlook is mixed: robust revenue growth and strategic acquisitions support long-term potential, but profitability challenges and bearish technical indicators present near-term risks. Investors should weigh strong analyst confidence against execution risks and current negative margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
